1. P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY. (5th April 2022) Authors: Rodríguez-Otero, P; San-Miguel, J; Anderson, LD; Lonial, S; Truppel-Hartmann, A; Sanford, J; Rowe, E; Campbell, TB; Munshi, N Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗